ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2513

The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab

Chamaida Plasencia-Rodriguez1, Dora Pascual-Salcedo2, Maria Gema Bonilla3, Alejandro Villalba1, Diana Peiteado1, Laura Nuño4, Pilar Aguado5, Teresa Jurado6, Emilio Martín-Mola7 and Alejandro Balsa8, 1Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 2Immunology, La Paz University Hospital, Madrid, Spain, 3Rheumatology Unit, La Paz University Hospital, Madrid, Spain, 4Hospital La Paz-IdiPaz, Madrid, Spain, 5Rheumatology, La Paz University Hospital-Idipaz, Madrid, Spain, 6Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, 7Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 8Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Clinical Response, infliximab and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose : There is a close association between serum Infliximab (Ifx) levels and the Antibodies To Infliximab (ATI) with the clinical activity in rheumatoid arthritis (RA) patients. Several markers have been described to predict the response to biological therapy but for now no evidence of serological markers during the TNFi therapy is available. Our aim was to analize whether Ifx drug levels at 2, 6 and 14 weeks after starting Ifx can predict the disappereance of serum Ifx levels and ATI detection at 6 months and 1 year in a cohort of RA patients treated with Ifx

Methods: 85 RA patients were included in this is ambispective observational study. The clinical activity was measured by DAS28 at baseline, 6 months and 1 year. The serum samples were obtained before each infusion at baseline, 2, 6 and 14 weeks after starting Ifx, 6 months and 1 year. Ifx and ATI levels were measured by ELISA. Receiver-operator characteristics (ROC) analysis were used to establish a cutt-off value for Ifx levels (2, 6 and 14 w) between patients with or without detectable Ifx levels at 6 months and 1 year. Area under the curve (AUC), sensitivity (S), specificity (SP) and positive likelihood ratio (LR+) were calculated at any studied point. The Last observation was carried forward (LOCF) for patients who dropped out before 1 year.

Results: Ifx levels at early stages (2, 6 and 14 weeks) of Ifx therapy were significantly lower in RA patients without detectable Ifx levels at 6 months and 1 year (Figure 1). Ifx levels lower than 21.2µg/ml at 2 weeks, 4.4µg/ml at 6 weeks and 0.4µg/ml at 14 weeks were predictive to Ifx disappearance at 6 months (2 weeks: AUC 0.708, S 67%, SP 87%, LR+5.1; 6 weeks: AUC 0.810, S 70%, SP 88%, LR+ 6.03; 14 weeks: AUC 0.923, S 83%, SP 92%, LR+10.4) and 1 year (2 weeks: AUC 0.708, S 64%, SP 89%, LR+5.8; 6 weeks: AUC 0.800, S 63%, SP 90%, LR+ 6.3; 14 weeks: AUC 0.923, S 75%, SP 94%, LR+13.1).

Conclusion: The monitoring of Ifx levels at early stages of therapy has a high value to discriminate which RA patients will have a faster Ifx clearance with the subsequent ATI detection and poor clinical outcomes. Patients with Ifx trough levels lower than 21.2, 4.4 and 0.4 µg/ml at 2, 6 and 14 weeks, respectively, have a high probability to develop ATI in the 1st year under the therapy. 

 

 

 


Disclosure:

C. Plasencia-Rodriguez,

Pfizer Inc,

2;

D. Pascual-Salcedo,

Pfizer Inc,

2;

M. G. Bonilla,
None;

A. Villalba,
None;

D. Peiteado,
None;

L. Nuño,
None;

P. Aguado,
None;

T. Jurado,
None;

E. Martín-Mola,
None;

A. Balsa,

Pfizer Inc,

9.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-monitoring-of-infliximab-levels-at-early-stages-can-predict-the-development-of-anti-infliximab-antibodies-in-a-cohort-of-rheumatoid-arthritis-patients-treated-with-infliximab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.